<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec><h3>BACKGROUND</h3>
<p>Stevens–Johnson syndrome and toxic epidermal necrolysis (TEN) are severe mucocutaneous adverse drug reactions primarily caused by drugs. Characterized by fever, prodromal symptoms, and extensive epidermal sloughing with mucous membrane involvement (>90%), they are collectively termed epidermal necrolysis and are considered a disease continuum.</p>
</sec>
<sec><h3>CASE PRESENTATION</h3>
<p>A 65-year-old man presented with widespread erythema and distinctive target-like lesions, accompanied by ruptured flaccid vesicles on the extremities. Following a 4-week carbamazepine treatment for a previous cerebrovascular insult, hematological analysis revealed abnormalities. A multidisciplinary team, including a neurologist, endocrinologist, and ophthalmologist, prescribed a 3-day course of intravenous immunoglobulin at 0.5 g/kg and an initial dose of 300 mg prednisolone for 3 days, supported by additional therapy. Discharged after 3 weeks, the rash completely resolved within 2 months.</p>
</sec>
<sec><h3>CONCLUSION</h3>
<p>TEN, a severe mucocutaneous condition with a 30% mortality rate, often results from drug exposure. Swift identification of the causative drug is crucial for optimal outcomes. Treatment primarily includes discontinuing the offending drug and offering supportive care for mucocutaneous lesions. A multidisciplinary approach is vital based on organ system involvement. The effectiveness of pharmacological treatments, such as intravenous immunoglobulin and corticosteroids, is continually under evaluation.</p>
</sec>
</abstract>

BACKGROUND
Stevens–Johnson syndrome and toxic epidermal necrolysis (TEN) are severe mucocutaneous adverse drug reactions primarily caused by drugs. Characterized by fever, prodromal symptoms, and extensive epidermal sloughing with mucous membrane involvement (>90%), they are collectively termed epidermal necrolysis and are considered a disease continuum.

CASE PRESENTATION
A 65-year-old man presented with widespread erythema and distinctive target-like lesions, accompanied by ruptured flaccid vesicles on the extremities. Following a 4-week carbamazepine treatment for a previous cerebrovascular insult, hematological analysis revealed abnormalities. A multidisciplinary team, including a neurologist, endocrinologist, and ophthalmologist, prescribed a 3-day course of intravenous immunoglobulin at 0.5 g/kg and an initial dose of 300 mg prednisolone for 3 days, supported by additional therapy. Discharged after 3 weeks, the rash completely resolved within 2 months.

CONCLUSION
TEN, a severe mucocutaneous condition with a 30% mortality rate, often results from drug exposure. Swift identification of the causative drug is crucial for optimal outcomes. Treatment primarily includes discontinuing the offending drug and offering supportive care for mucocutaneous lesions. A multidisciplinary approach is vital based on organ system involvement. The effectiveness of pharmacological treatments, such as intravenous immunoglobulin and corticosteroids, is continually under evaluation.

Toxic Epidermal Necrolysis: Case Report and Review

University Clinic for Eye Diseases. Ss Cyril and Methodius University of Skopje

University Clinic for Plastic and Reconstructive Surgery, Ss Cyril and Methodius University of Skopje

South East European Journal of Immunology

This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.

{"article-title":"Toxic Epidermal Necrolysis: Case Report and Review"}

BACKGROUND
Stevens–Johnson syndrome and toxic epidermal necrolysis (TEN) are severe mucocutaneous adverse drug reactions primarily caused by drugs....

Toxic Epidermal Necrolysis: Case Report and Review

Pubblicato online: 07 giu 2024

Pagine: 56 - 60

Ricevuto: 08 gen 2024

Accettato: 28 feb 2024

DOI: https://doi.org/10.3889/seejim.2024.6075

Parole chiave
Stevens–Johnson syndrome, Toxic epidermal necrolysis, Mucocutaneous reaction, Carbamazepin

© 2024 Hristina Breshkovska et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.

Toxic Epidermal Necrolysis: Case Report and Review

Pubblicato online: 07 giu 2024

Pagine: 56 - 60

Ricevuto: 08 gen 2024

Accettato: 28 feb 2024

DOI: https://doi.org/10.3889/seejim.2024.6075

Parole chiaveStevens–Johnson syndrome, Toxic epidermal necrolysis, Mucocutaneous reaction, Carbamazepin

© 2024 Hristina Breshkovska et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.

Parole chiave
Stevens–Johnson syndrome, Toxic epidermal necrolysis, Mucocutaneous reaction, Carbamazepin